摘要
目的:分析分子靶向抗肿瘤药的使用情况,为临床合理使用提供参考。方法:采用回顾性调查方法,对南京地区33家医院2014~2016年分子靶向抗肿瘤药物的用药金额、用药频度(DDDs)、限定日费用(DDC)及排序比(B/A)进行分析。结果:南京地区33家医院分子靶向抗肿瘤药销售金额由2014年的8 082.23万元增加至2016年的10 970.18万元,增长了35.73%。其中,单克隆抗体药的销售金额构成比逐年上升,酪氨酸激酶抑制药的销售金额构成比逐年下降。利妥昔单抗各年度销售金额均排名前列。吉非替尼连续3年DDDs排名第1,DDDs较高。大部分药物DDC相对稳定,B/A值大于1,销售金额与用药频度同步性总体较好。结论:2014~2016年南京地区分子靶向抗肿瘤药应用呈上升趋势,分子靶向药物越来越得到临床认可。
Objective ：To analyze the utilization and tendency of use of molecular targeted anti-tumor drugs in the clinic. Methods： In retrospective survey, the utilization of molecular targeted anti-tumor drugs were statisticaily analyzed in 33 hospitals from Nanjing area during 2014-2016. In terms of consumption sum, DDDs, DDC and B/A. Results：The consumption sum of molecuar targeted anti-tumor drugs increased from 8 082.23 ten thousand yuan in 2014 to 10 970.18 ten thousand yuan in 2016, with annual growth rate of 35.73%. The consumption sum ratio of sillgle-molecule anti-body agent increased year by year, while the tyrosine kinase inhibitor decreased year by year. Rituxinlab took up the front in the list of annual consumption sum. Gefitinib remained the top 1 places in the list of DDDs and were used frequently. DDC of most of molecular targeted anti-tumor drugs kept stable relatively, and the B/A were more then 1. Conclusion：The consumption of molecular targeted anti-tumor drugs in Nanjing are upward trend from 2014 to 2016, indicating the increasing popularity of molecular targeted drugs.
作者
黄莉莉
王羽
李京京
Huang Lili1, Wang Yu1 , Li Jingling(1. Department of Pharmacy, Drum Tower Hospital affiliated to School of Medicine, Nanjing University, Nanjing 210008, China; 2. Nanjing Children＇s Hospita)
出处
《药物流行病学杂志》
CAS
2018年第4期254-258,共5页
Chinese Journal of Pharmacoepidemiology
关键词
分子靶向药物
抗肿瘤药
用药频度
药物利用
南京地区
Molecular targeted rugs
Anti-tumor drugs
DDDs
Analysis of drug utilization
Nanjing area
